Protection Against Visible Light by Dihydroxyacetone in Erythropoietic Protoporphyria

Bispebjerg Hospital

Status: Enrolling

Conditions: Erythropoietic Protoporphyria

Treatments: Other: Dihydroxyacetone; Other: Placebo

Study type: Interventional

Funder types: Other

Identifiers

NCT05780840

Dihydroxyacetone

Details and patient eligibility

About

What is the visible light protective effect of dihydroxyacetone in individuals with erythropoietic protoporphyria? This will be tested in this randomized blinded placebo controlled study.

Enrollment: 6 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Diagnosed with erythropoietic protoporphyria
• At least 18 years of age
• Obtainment of written informed consent

Exclusion criteria

• Pregnant or breastfeeding
• Use of dihydroxyacetone at the treatment or placebo fields within the last two week
• Sun exposure of the treatment or placebo fields within the last two week
• Use of suncreen or other local treatment on the treatment or placebo fields during the study period (two days)
• Allergy to adhesive bandages, dihydroxyacetone or lotion

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Single Blind

---

6 participants in 2 patient groups, including a placebo group

Dihydroxyacetone

Experimental group

Treatment:

Other: Dihydroxyacetone

Other: Placebo

Placebo

Placebo Comparator group

Treatment:

Other: Dihydroxyacetone

Other: Placebo